InSite Vision raises $22.2 million

Thursday, July 14, 2011 12:28 PM

InSite Vision has entered into a private placement financing transaction of approximately $22.2 million in exchange for the issuance of approximately 37 million shares of InSite Vision common stock and warrants to purchase approximately 14.8 million shares of InSite Vision common stock.

InSite Vision will use the net proceeds to fund clinical trials and for general corporate purposes, including working capital.

Piper Jaffray & Co. served as sole placement agent and JMP Securities served as financial advisor in connection with the transaction.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs